XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 131,003,000 $ 113,688,000
Short-term investments 0 121,898,000
Accounts receivable, net ($15,534 and $6,079 from related parties) 29,030,000 12,553,000
Inventories 23,937,000 41,565,000
Prepaid expenses and other current assets ($24,785 and $0 from a related party) 60,559,000 41,855,000
Total current assets 244,529,000 331,559,000
Restricted time deposits 1,658,000 1,658,000
Property and equipment, net 7,603,000 13,126,000
Equity method investment in unconsolidated variable interest entity 5,806,000 5,290,000
Operating lease right-of-use assets 2,093,000 68,093,000
Other assets 2,732,000 3,803,000
Total assets 264,421,000 423,529,000
Current liabilities:    
Accounts payable ($2 and $0 to a related party) 9,238,000 17,960,000
Accrued and other current liabilities ($12,592 and $39,814 to a related party) 151,141,000 172,891,000
Deferred revenue ($6,723 and $7,220 to related parties) 28,858,000 12,740,000
Operating lease liabilities, current 1,293,000 14,077,000
Total current liabilities 190,530,000 217,668,000
Product development obligations 18,199,000 17,763,000
Deferred revenue, net of current ($1,388 and $9,705 to a related party) 126,219,000 157,555,000
Operating lease liabilities, non-current 707,000 66,537,000
Senior secured term loan facilities, non-current 72,779,000 71,934,000
Liability related to sale of future revenues, non-current 56,850,000 51,413,000
Other long-term liabilities ($559 and $656 to a related party) 837,000 2,858,000
Total liabilities 466,121,000 585,728,000
Commitments and Contingencies
Redeemable non-controlling interests 21,480,000 21,480,000
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023
Common stock, $0.01 par value; 225,000 shares authorized at September 30, 2024 and December 31, 2023; 100,770 and 98,770 shares issued and outstanding at September 30, 2024 and December 31, 2023 1,008,000 988,000
Additional paid-in capital 1,668,434,000 1,643,641,000
Accumulated other comprehensive loss (5,628,000) (6,875,000)
Accumulated deficit (1,907,481,000) (1,841,920,000)
Total stockholders' deficit attributable to FibroGen (243,667,000) (204,166,000)
Nonredeemable non-controlling interests 20,487,000 20,487,000
Total deficit (223,180,000) (183,679,000)
Total liabilities, redeemable non-controlling interests and deficit $ 264,421,000 $ 423,529,000